Cancer Research Cell Death Mechanisms and Cancer Therapy Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDaid, H. M.
Right arrow Articles by Band Horwitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDaid, H. M.
Right arrow Articles by Band Horwitz, S.
[Cancer Research 65, 2854-2860, April 1, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants

Hayley M. McDaid1,2, Lluis Lopez-Barcons1,2, Aaron Grossman1, Marie Lia2, Steven Keller3, Román Pérez-Soler2 and Susan Band Horwitz1

Departments of 1 Molecular Pharmacology and 2 Medicine, Albert Einstein College of Medicine and 3 Department of Cardiothoracic Surgery, Montefiore Medical Center, Bronx, New York

Requests for reprints: Hayley McDaid, Department of Molecular Pharmacology, Albert Einstein College of Medicine, Golding 201, 1300 Morris Park Avenue, Bronx, NY 10461. Phone: 718-430-2192; Fax: 718-430-8959; E-mail: mcdaid{at}aecom.yu.edu.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Taxol may contribute to intrinsic chemoresistance by activating the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) cytoprotective pathway in human cancer cell lines and tumors. We have previously shown additivity between Taxol and the MEK inhibitor, U0126 in human cancer cell lines. Here, the combination of Taxol with an orally bioavailable MEK inhibitor, CI-1040, was evaluated in human lung tumors heterotransplanted into nude mice. Unlike xenograft models that are derived from cells with multiple genetic alterations due to prolonged passage, heterotransplanted tumor models are more clinically relevant. Combined treatment with both drugs resulted in inhibition of tumor growth in all models and tumor regressions in three of four models tested, supporting our previous observation that Taxol's efficacy is potentiated by MEK inhibition. Concurrent administration was superior to intermittent dosing. Pharmacodynamic assessments of tumors indicated that suppression of MEK was associated with induction of S473 phosphorylated Akt and reduced proliferation in the combination groups relative to single agents, in addition to suppression of fibroblast growth factor–mediated angiogenesis and reduced expression of vascular endothelial growth factor. These findings are significant and indicate that this combination may have broad therapeutic applications in a diverse range of lung tumors with different intrinsic chemosensitivities.

Key Words: Taxol • CI-1040 • Combination treatment • Heterotransplanted tumor models • Non–Small Cell Lung Cancer (NSCLC)


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Aberrant signaling is a hallmark of tumorigenesis and there has been an explosion in the search for molecular targets that are amenable for pharmacologic intervention (1). It is anticipated that optimal use of molecular targeted therapies will be in combination therapy, whether with classic cytotoxic drugs, or with other targeted therapies. Cytotoxic or molecular targeted therapies may inappropriately induce the expression of cytoprotective signaling cascades that can mediate resistance. The use of a novel combination to circumvent this possibility is explored herein, and this strategy may be effective in immobilizing the survival and proliferative capacity of tumors.

The mitogen-activated protein kinase (MAPK) signaling family transduces signals that regulate embryogenesis, proliferation, homeostasis, and cell death (2), primarily via phosphorylation. Three major MAPK pathways have been identified in mammalian cells. Constitutive activation of the extracellular signal-regulated kinase (ERK) pathway results from defects in multiple oncogenic pathways including the epidermal growth factor receptor family (EGFR and HER-2/neu), vascular endothelial growth factor (VEGF), platelet derived growth factor, and mutated Ras (3) or Raf (4). Hence, inhibition of the MAPK kinase (MEK)/ERK pathway is a validated target in cancer treatment. MEKs (MEK1 and MEK2) are attractive chemotherapeutic targets because of their unusually restrictive substrate specificity (5). Signal amplification of the ERK cascade occurs at the Raf-MEK stage (6) and aberrant MEK/ERK activity has been observed in a number of primary human tumors (7, 8). The development of MEK inhibitors such as CI-1040, an orally active and highly potent inhibitor that has completed phase I/II clinical evaluation, has progressed rapidly (9, 10). CI-1040 and its analogues have a unique inhibitor-binding pocket adjacent to the MgATP-binding site of MEK1 and MEK2 (11).

The role of MEK/ERK in the control of the G1 phase of the cell cycle has been well documented (12); however, MAPKs are also required for mitosis and meiosis (4, 13–16). Activated ERKs localize at kinetochores, asters, and the midbody during mitosis (17), presumably to facilitate interaction with proximal substrates that are involved in mitotic spindle function. It has also been shown that some 40% of ERKs colocalize to microtubules (18) and that ERK2 specifically interacts with the actin-microtubule cytoskeleton (19). In view of the association between microtubules and MEK/ERKs, one would predict that perturbation of microtubules by Taxol alters the expression of proteins that are associated with microtubules. We have previously shown that Taxol activates the MEK/ERK pathway (20) and that the efficacy of Taxol is potentiated by MEK inhibition. Similar findings have been reported by other groups (21, 22).

This report describes enhanced activity of Taxol by CI-1040 in vivo using human heterotransplanted non–small cell lung cancer (NSCLC) tumors grown in nude mice (23). This potentiation of Taxol activity was associated with altered expression of specific proteins, including proliferating cell nuclear antigen (PCNA), VEGF, and S473 phosphorylated Akt (protein kinase B). These in vivo studies support our previous findings and show activity of this combination in a number of diverse NSCLC tumor models with differential intrinsic sensitivity to Taxol.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals and tumor implantations. The human NSCLC cell line, A549 was maintained as previously described (20). Either 4 x 106 A549 NSCLC cells (xenograft), or minced fragments of NCSLC tumors from patients (heterotransplants) were injected s.c. into the right axillary region of 6-week-old athymic (nu/nu) female mice (Harlan Sprague-Dawley, Inc., Indianapolis, IN). Tumors were collected from consenting patients under institutional review board approval. Tumors were allowed to grow until a volume of ~100 mm3 and mice were randomized into balanced groups. Clinical grade Taxol was given by i.p. injection in five separate doses every 3 days (q3dX5). CI-1040 (PD184352) was obtained from Pfizer (Ann Arbor, MI) and was given orally (p.o.) three times a day (TID), as a suspension in 0.5% hydroxypropylmethylcellulose/0.2% Tween 80 (see Supplementary Fig. S1 for determination of optimal dosing). Maintenance dosing of CI-1040 twice daily (BID), including weekends, was done in mice receiving CI-1040 alone and in combination groups from day 16 after drug treatment initiation (when Taxol administration was complete) until the termination of each experiment. End points (body weight, tumor volume, and toxicities) were measured weekly for the duration of experiments, which were done with Animal Institute Committee approval and in compliance with policies for ethical animal use and federal, state and local regulations. Tumor volumes were calculated from the formula (l x w2) / 2, where l and w are length and width of the tumor, respectively. Antitumor activity was expressed as relative tumor volume, (T / T0) x 100, where T is the mean tumor volume at a particular time and T0 is the mean tumor volume at day 0. Statistical significance was evaluated using either a one-tailed Student's t test, or a repeated measure one-way ANOVA test with Newman-Keuls multiple comparison post test.

Matrigel plug analysis and Drabkins assay. Nude mice were anesthetized and injected s.c. in the lower abdomen with 0.5 mL of matrigel basement membrane matrix (BD Biosciences, San Jose, CA) supplemented with 1 ng/µL bovine fibroblast growth factor (FGF). Groups of mice (n = 4) were randomized and treated 24 hours later with drugs. Animals were euthanized at day 14 after dosing and matrigel plugs excised and processed as previously described (24).

Immunoblotting. Tumor cell extracts were prepared by mechanical homogenization at 4°C in nondenaturing lysis buffer as described previously (20) with 10 mmol/L NaF, 2 mmol/L Na3VO4, and 1 µmol/L microcystein. The antibodies used were Phospho-p44/42 MAPK (Thr202/Tyr204), Phospho-AKT (Ser473), Phospho-Erk5 (Thr218/Tyr220), ERK5 (all from Cell Signaling Technologies, Beverly, MA); PCNA (NeoMarkers, Vermont, CA); Cox-2, VEGF, ERK2, AKT 1/2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); and glyceraldehyde 3-phosphate dehydrogenase, G3PDH (Trevigen, Gaithersburg, MD).

Immunohistochemistry. Formalin-fixed specimens were processed and analyzed for phospho-p44/42MAPK (Thr202/Tyr204) expression using a rabbit monoclonal antibody (Cell Signaling Technologies), according to the manufacturers' recommendations. Slides were incubated in diaminobenzidine/hydrogen peroxide as the chromogen/substrate with 3,3'-diaminobenzidine enhancer and counterstained in hematoxylin. The mitotic index (the mean number of mitotic figures per 10 high power fields) was determined from analysis of H&E-stained sections at 40x magnification.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Concurrent administration of CI-1040 potentiates the efficacy of Taxol in an A549 xenograft model of non–small cell lung cancer. A459 NSCLC xenografts were chosen for optimization of dosing and schedules in vivo because (i) this cell line was used in our in vitro studies (20) and (ii) A549 cells proliferate rapidly in vivo; therefore, dose optimization would potentially be applicable to other tumor models with comparable or reduced proliferation. Eight animals per treatment group were used. Control animals received normal saline i.p. and 0.5 mL hydroxypropylmethylcellulose/0.2% Tween 80 p.o. CI-1040 was given at 150 mg/kg TID (Supplementary Fig. S1). Initially, two different doses of Taxol, either 20 mg/kg q3dX5, or 50 mg/kg qweek x2 i.p., for a total dose of 100 mg/kg, were evaluated (Fig. 1A). The dose of Taxol was determined from previous studies (25). Justification for weekly dosing was from ongoing clinical trials of weekly Taxol in a number of disease types, including NSCLC (26). Concurrent dosing of Taxol with CI-1040 was evaluated initially, because our in vitro studies determined this to be the most effective (20). Tumor volumes in mice that received either CI-1040 or Taxol, at either dose, were significantly smaller than tumor volumes in control mice (Fig. 1A; P < 0.05, ANOVA). None of the single agent treatments resulted in tumor regression, although all inhibited tumor growth to varying degrees. Mice that received the combination of CI-1040 with either schedule of Taxol had tumor regressions and tumor volumes were significantly smaller than those treated with single agents (P = 0.027, ANOVA). Combination group A (concurrent combination of CI-1040 and 20 mg/kg q3dX5 Taxol) was superior to combination B (concurrent combination of CI-1040 and 50 mg/kg qweek Taxol), in terms of the duration of tumor regression (time for actual mean tumor volumes to reach 300 mm3 was ~23 days for combination B versus 29 days for combination A). Combination A was associated with transient gastrointestinal toxicities (diarrhea with hematochezia) in two of eight mice that resolved upon completion of Taxol dosing. Weight loss data are available in Supplementary Fig. S2. Animals from the experiment depicted in Fig. 1A were sacrificed at day 8 post-treatment initiation and the xenografts analyzed by immunoblotting (Fig. 1B). Treatment with CI-1040 alone, or in combination with Taxol, suppressed phosphoERK relative to untreated tumors. Consistent with previous data (20), we observed a slight activation of phosphoERK in the lysates of Taxol-treated xenografts.



View larger version (35K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Optimization of Taxol and CI-1040 therapy in A549 xenografts in vivo. A, antitumor effects of CI-1040 in combination with Taxol given weekly or q3day. Animals were treated as described in Materials and Methods. Maintenance dosing of 150 mg/kg BID CI-1040 was performed from day 16 after drug treatment initiation. Points, relative mean tumor volume per group; bars, ±SE. Dashed line, initial tumor volume. Green arrows, Taxol administration q3dX5; and yellow arrows, Taxol doses q week. B, pharmacodynamic evaluation of phosphorylated ERK. Mice from the experiment described in A were sacrificed after three cycles of Taxol (day 8). Doses of drugs are as follows: CI-1040 (150 mg/kg TID, p.o.) and Taxol (20 mg/kg q3dX5, i.p.). Expression was relative to G3PDH. C, intermittent dosing of CI-1040 and Taxol. As in A, animals were treated as described in Materials and Methods. Green arrows, days when Taxol was given.

 
The effect of schedule on antitumor efficacy and toxicity was assessed by intermittent dosing (defined as stopping and starting CI-1040 at intervals), illustrated in Fig. 1C. Two dosing strategies were evaluated. In the first, Taxol was given on days 1, 4, 7, 10, and 13 and CI-1040 was given 24 hours later on days 2, 5, 8, 11, and 14. Neither drug was given on day 3, 6, 9, or 12 and maintenance dosing of CI-1040 was initiated on day 16. Compared with concurrent administration that resulted in sustained tumor regressions up to days 22 to 23 post-treatment initiation, this schedule was less effective (P = 0.04, t test) and tumor regressions were not observed. In the second dosing strategy, both Taxol and CI-1040 were given on days 1, 4, 7, 10, and 13. This was even less effective in terms of antitumor efficacy and xenograft growth in this group was not statistically different from the growth of tumors treated with Taxol alone. No weight loss or gastrointestinal toxicities were observed with either sequencing regimen. The time for actual mean tumor volumes to reach 300 mm3 was ~27 days for the concurrent combination versus 22 days for either intermittent dosing regimen. Sequential administrations were also evaluated, whereby each drug was given after one another (data not shown); for example, CI-1040 was given 13 days post-treatment initiation when Taxol dosing was complete. However, no enhancement of antitumor efficacy relative to single agents was observed. Therefore, the most effective enhancement of Taxol's cytotoxic potency was obtained via continual suppression of MEK through concurrent administration of both drugs, which was used in all subsequent experiments. Any form of intermittent dosing was associated with reduced antitumor efficacy.

CI-1040 potentiates the efficacy of Taxol in heterotransplanted models of lung cancer. The concurrent combination of Taxol with CI-1040 that was optimized in A549 xenografts was evaluated in heterotransplanted tumor models (Fig. 2). These included two adenocarcinomas (HTL-13 and HTL-25) derived from patients with stage II and stage I metastatic disease, respectively. A squamous tumor model (HTL-34) that was derived from a patient with stage I disease was also evaluated. Tumors that were grown for three passages in nude mice were used in all experiments. Standard H&E staining of archived tissue from heterotransplants grown in mice at each passage was done and these analyses confirmed retention of the original tumor histology (data not shown). Approximately four to six animals per treatment group were used. All experiments used concurrent dosing of the combination (150 mg/kg CI-1040 TID with 20 mg/kg Taxol q3dX5) and BID maintenance dosing of CI-1040 was done from day 16, until the termination of each experiment.



View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Effects of concurrent Taxol and CI-1040 therapy in heterotransplanted lung tumor models. A, HTL-13; B, HTL-34; C, HTL-25. Animals were treated as described in Materials and Methods. Points, relative mean tumor volume per group; bars, ±SE. Dashed line, initial tumor volume. Arrows, days when Taxol was given.

 
The adenocarcimona tumor model, HTL-13, was resistant to treatment with either Taxol or CI-1040 as single agents (Fig. 2A). Despite this, the concurrent combination decreased the proliferation rate of tumors (P < 0.05, ANOVA) relative to single agents (time for actual mean tumor volumes to reach 300 mm3 was ~7 days for single agents versus ~15 days for the combination). No tumor regressions were observed. The combination treatment was associated with ~5% weight loss and transient diarrhea and hematochezia in one of six mice.

HTL-34 was a chemosensitive tumor model (Fig. 2B), in that treatment with single agents induced statistically significant suppression of tumor growth compared with untreated control tumors (P < 0.01, ANOVA). The concurrent combination of Taxol and CI-1040 induced tumor regressions that were significantly different (P < 0.01, ANOVA) from single agents (time to reach actual mean tumor volumes of 300 mm3 was ~44 days for the concurrent combination, versus 10 days for Taxol and 13 days for CI-1040). The combination treatment was associated with ~5% to 8% weight loss and transient diarrhea in two of six mice.

HTL-25 was a slowly proliferating, chemosensitive tumor model and the duration of this experiment exceeded 120 days (Fig. 2C). Similar to HTL-34, treatment with either Taxol or CI-1040 induced significant reductions in tumor growth relative to untreated control tumors (P < 0.05, ANOVA). The concurrent combination of Taxol and CI-1040 induced tumor regressions that were significant at defined times only (at day ~20 and again after day 60: P = 0.05, t-test) relative to single agents. This is likely due to the fact that Taxol and CI-1040 alone induced regressions of ~2% and 7%, respectively, of the initial tumor volumes. The time to reach actual mean tumor volumes of 300 mm3 was ~48 days for control tumors versus 88 days for Taxol, 100 days for CI-1040, and 130 days for the concurrent combination. The combination treatment was associated with ~5% weight loss and transient diarrhea in one of six mice.

Analysis of drug-treated tumors by immunoblotting. Animals from each treatment group were euthanized and tumors were excised and analyzed by immunoblotting. Representative data for HTL-13 are shown in Fig. 3A. Phospho-ERK was suppressed in tumors treated with CI-1040 alone and in combination, and there was no increase in the expression of phospho-ERK in Taxol-treated tumor cells. Consistent with the decreased proliferation of tumors undergoing concurrent treatment (Fig. 2A), tumor cells had decreased expression of the proliferation specific antigen, PCNA, relative to single agents. Decreased expression of vascular endothelial growth factor, VEGF, relative to single agent treatment was also observed. A recent report has shown suppression of VEGF by CI-1040 (27), although both CI-1040 and Taxol as single agents increased VEGF in HTL-13. Furthermore, CI-1040 treatment whether alone, or in combination, increased expression of S473 phosphorylated Akt, which together with phosphorylation of T308, is associated with constitutively active Akt (28). Reciprocal signaling between the MEK/ERK and PI3K/Akt pathways (29–31) has been reported. The combined treatment of Taxol with U0126 has been reported to suppress Akt kinase activity and this may contribute to the cell death–inducing potency of this combination (32). Although these findings are not supported for HTL-13, it should be noted that tumor regressions also were not observed.



View larger version (37K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3. Immunoblot analysis of heterotransplanted tumors. Tumors were collected at defined times after drug treatment and analyzed. Animals were treated as described in Materials and Methods. A, HTL-13 tumors at day 8. B, HTL-34 tumors at day 11. C, HTL-25 tumors at day 11. Note change in order of lysates for C.

 
Representative data from HTL-34 (Fig. 3B) showed suppression of phospho-ERK, relative to the untreated control tumors in all groups, as well as decreased expression of PCNA. VEGF expression was dramatically suppressed in CI-1040 and Taxol-treated tumors and also decreased with concurrent treatment. CI-1040 alone increased the expression of S473 phosphorylated Akt, whereas the concurrent combination, or Taxol alone had levels of expression comparable to control tumors.

Representative data from HTL-25 indicated suppression of phospho-ERK by CI-1040 and the combination treatments (Fig. 3C). PCNA expression did not substantially change during the course of treatment with either single agents or the combination, presumably due to the slow proliferation rate of this tumor. VEGF expression was suppressed in both CI-1040- and Taxol-treated tumor cells and was dramatically suppressed by the concurrent combination treatment (Fig. 3C). Similar to the data presented in Fig. 3A, S473 phosphorylated Akt expression increased in CI-1040 and in combination treated tumors (Fig. 3C).

Immunohistochemical analysis of phospho–extracellular signal-regulated kinase expression in heterotransplants. As a complement to the immunoblot analysis of tumors, immunohistochemical staining of fixed tumors was done (Fig. 4). Staining localized to both nuclear and cytoplasmic regions, with intense immunoreactivity in nuclei. Infiltrating mouse stromal tissue was unreactive. HTL-13 (A-D) showed primarily strong nuclear staining. Consistent with Fig. 3A, CI-1040 treatment resulted in decreased staining. Although the expression of pERK decreased overall in the combination treatment, there were a number of strongly immunoreactive multinucleated cells (D). Taxol-induced activation of phospho-ERK was evident in HTL-34 and A549 tumor models (F and N), whereas suppression of phospho-ERK by CI-1040 was apparent in HTL-13, HTL-25, and A549 tumor models (C, K, and O). Interestingly, the only tumor model to exhibit conclusive diminished phospho-ERK immunoreactivity with the combination treatment was HTL-25 (L). Both HTL-34 and A549 retained strong phospho-ERK staining with the combination treatment (H and P) with intense staining of multinucleated, or aberrant cells, similar to what was observed in HTL-13.



View larger version (124K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 4. Immunohistochemical analysis of Phospho-ERK in heterotransplanted tumors. HTL-13 (A-D: 100x magnification), HTL-34 (E-H, 10x magnification), HTL-25 (I-L, 10x magnification), and A549 (M-P, 10x magnification). Sections were counterstained with hematoxylin. Control tumors (A, E, I, and M), Taxol-treated tumors (B, F, J, and N), CI-1040-treated tumors (C, G, K, and O), and combination treated-tumors (D, H, L, and P). Mitotic indices (mean ± SD) determined from analysis of H&E-stained sections.

 
Decreased proliferation by the combination treatment was confirmed from the mean mitotic indices determined from the quantitation of mitotic cells in H&E-stained tumor sections. All tumors models treated with the concurrent combination had a reduction in mitotic cells consistent with the decreased expression of PCNA presented in Fig. 3, although the effects of drug treatments were minimal in HTL-25. Ki-67 staining was also decreased by the combination treatments, consistent with decreased mitotic index. Cell death, as determined by terminal deoxynucleotidyl transferase–mediated nick end labeling staining, was increased (Supplementary Fig. S3).

Inhibition of fibroblast growth factor–stimulated angiogenesis by CI-1040 and Taxol. The matrigel plug assay was used to determine the angiogenic response to treatment. The Drabkins method provides an index of blood containing vessels by quantifying the hemoglobin content of the matrigel. There was little angiogenesis in control plugs that had not been supplemented with FGF (data not shown). FGF-supplemented plugs had a moderate angiogenic response that was not significantly inhibited by treatment with Taxol alone but was significantly inhibited by CI-1040 (P = 0.02, t test; Fig. 5). Those matrigels treated with the concurrent combination of Taxol and CI-1040 showed suppression of angiogenesis that was significantly different from single agents, CI-1040 (P = 0.05, t test) and Taxol (P = 0.01, t test).



View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 5. Effect of MEK inhibition and Taxol on FGF-stimulated angiogenesis. FGF-supplemented matrigel plugs were implanted and 14 days post-treatment, animals were euthanized and matrigel plugs excised and analyzed. Hemoglobin content per gram of matrigel was calculated. Columns, mean values per treatment group expressed relative to untreated controls; bars, ±SE. * represents statistical significance relative to control. Matrigels treated with the concurrent combination contained significantly less hemoglobin relative to single agents, CI-1040 (P = 0.05, t test) and Taxol (P = 0.01, t test).

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
Here we describe signifcant potentiation of Taxol-induced efficacy by the MEK inhibitor, CI-1040, that is optimal with concurrent dosing in human heterotransplanted NSCLC tumor models. These tumor models are more clinically relevant compared with cell lines that are grown as xenografts. They recapitulate the distinct pharmacogenomic profiles and differential chemotherapeutic responses of patients as well as histology, chromosome complement, antigen expression, and gene expression. It previously has been shown that human tumor heterotransplant models have patient response prediction rates of 90% and 97% for chemosensitivity and chemoresistance, respectively (33). The studies described here used s.c. "early-stage" tumors, in that treatments were initiated when tumors were palpable (around 100 mm3), which mimics adjuvant chemotherapy of patients with early stage or resected disease. In phase I, CI-1040 was well tolerated BID or TID, with stable disease in 25% of patients (9). Phase II studies showed excellent tolerability and minimal single agent activity, which was attributed to insufficient drug exposure (10), possibly due to metabolic degradation (34). Another MEK inhibitor, PD0325901 has exquisite specificity for MEK1 and an improved pharmaceutical profile culminating in enhanced solubility and bioavailability (10). The chemotherapeutic merit of MEK inhibitors will be explored by the ongoing clinical trials of PD0325901, although the true potential of these drugs may be in combination chemotherapy.

Each heterotransplanted tumor model described here had a differential response to either Taxol or CI-1040 as single agents, but all tumors showed potentiation of Taxol's antitumor efficacy by CI-1040. The antitumor efficacy of combined Taxol and MEK inhibition was superior in A549, HTL-34, and HTL-25 models where tumor regressions were obtained. Two of the six HTL-34 mice in the combination group had sustained regressions 10 months after dosing of CI-1040 and Taxol had terminated. In the chemoresistant tumor model, HTL-13, treatment with CI-1040 or Taxol alone was ineffective, yet the combination treatment had increased efficacy, relative to either single agent that was associated with suppressed proliferation. This suggests a broad therapeutic application for this drug combination in NSCLC. One of the potential mechanisms for the interaction between Taxol and MEK inhibition is inadvertent induction of MEK/ERK signaling by Taxol treatment, due to the accumulation of cells in the G2-M phase of the cell cycle. This activation increases the abundance of MEK, the target of CI-1040, leading to enhanced efficacy of the combination. In addition, it may increase the rate of mitotic catastrophe, due to the absolute requirement of ERK/MEK for the successful execution of mitosis. Our previous study (20) suggested that the nature of the interaction between Taxol and MEK inhibition in cancer cells may be dependent on the level of constitutive ERK activation and the degree to which cells undergo Taxol-induced ERK activation. Interestingly, those tumor models that showed Taxol-induced ERK activation by immunohistochemistry (HTL-34, HTL-25, and A549) also showed the most promising antitumor response, although the significance of this should not be overstated, taken the small sample number evaluated.

Numerous Taxol and CI-1040 sequencing regimens were analyzed in this study due to the attention surrounding the INTACT trials (35, 36). Despite 5% to 10% response rates for the EGFR tyrosine kinase inhibitor, gefitinib, in discrete populations of NSCLC, there was no benefit to adding it to existing taxane or platinum containing chemotherapy (37). The failure of gefitinib in combination therapy may have been due to inappropriate scheduling, or perturbations of the cell cycle that impeded the efficacy of cytotoxic drugs (38). Ongoing combination trials of another EGFR inhibitor, erlotinib with carboplatin and paclitaxel (TRIBUTE) and gemcitibine and cisplatin (TALENT) reported no clinical benefit (39). Furthermore, a recent clinical trial showed no clinical benefit for the administration of Trastuzumab in combination with cisplatin and gemcitabine in NSCLC, although it has been suggested that this was due to the predominately low to intermediate HER expression status of patients accrued (40). The foundations for these clinical trials were based on in vivo xenograft data and there are numerous reasons for the disparity between the two. The most obvious is that the schedule used in the animal studies was different from the schedule used in the clinical trial. In addition, preclinical drug combination studies are usually done between two agents, whereas these clinical trials used molecular-targeted therapies added to a chemotherapy doublet. Finally, patients enrolled on these studies were not preselected for overexpression of receptors or mutational status, the very factors that may be the most important determinants of response rates. The optimal administration of cytotoxic and molecular targeted therapies continues to be a subject of debate; however, we have determined concurrent administration to be most favorable for Taxol and CI-1040.

Phospho-ERK status was evaluated by immunoblotting and immunohistochemistry as a correlate of response to CI-1040. All of the four tumor models showed suppression of phospho-ERK by CI-1040 (where data was complementary by immunoblotting and immunohistochemistry for three of four models). The response to CI-1040 was somewhat related to the degree of constitutive expression of the ERK/MEK signaling cascade, although HTL-13 had moderate expression of this pathway yet had no therapeutic response to CI-1040, despite suppression of phospho-ERK. Thus, it is our contention that MEK/ERK overexpression alone is not a sufficiently accurate predictor of response to MEK inhibition therapies. The Akt signaling pathway has been shown to be deregulated in a number of cancer types and there is evidence to suggest that phospho-Akt overexpression in NSCLC confers a stage-independent survival disadvantage (41). Activated Akt promotes cell survival by inhibiting cell death via phosphorylation and inactivation of several targets (42, 43) . Moreover, cross-talk has been shown between MAPK and PI3K at the level of Raf and Akt (29). This finding is supported by our data as all three heterotransplanted tumor models showed phosphorylation of AKT at S473 by CI-1040. Phosphorylation of AKT by MEK inhibitors have been noted elsewhere (44, 45). A recent study attributes resistance to trastuzumab, the humanized monoclonal antibody against ErbB2, to loss of PTEN function (46). It is plausible that a similar explanation for chemoresistance to MEK inhibitors exists.

CI-1040 alone, and in combination with Taxol, suppressed FGF-mediated angiogenesis in vivo and decreased VEGF expression. It has been suggested that Erk5 may play an important role in controlling angiogenesis (47, 48). It is conceivable that the suppression of VEGF and FGF-induced angiogenesis are mediated via CI-1040-induced suppression of ERK5. CI-1040 and other commercially available MEK inhibitors are known to inhibit ERK5, albeit at 10-fold higher concentrations than that required for MEK1/MEK2 inhibition (49). We did not find any evidence to support altered expression of phospho-ERK5 in this study or in in vitro analyses of A549 cells (data not shown). Therefore, it is unlikely that the anti-angiogenic effects of CI-1040 are mediated via ERK5 suppression. Furthermore, it has been suggested that MEK inhibition also suppresses cyclooxygenase 1 and 2 (50). Although this may be the case for PD98059 (51), we found no evidence of altered cyclooxygenase 1 or 2 expression with CI-1040.

Activation of cytotoprotective signaling in tumor cells, whether intrinsic or chemotherapy induced, is a phenomenon that may be more prevalent than previously thought. Thus, acquired resistance to drugs, such as Taxol, may be due to acute activation of survival pathways such as MEK, during chemotherapy administration. We have shown impressive potentiation of Taxol's antitumor efficacy in vivo in human xenograft tumor models by coadministration with CI-1040, an orally bioavailable MEK inhibitor. Enhanced antitumor activity was associated with reduced proliferation and suppression of angiogenesis. We propose that this drug combination and the principle of suppressing cytoprotective signaling during chemotherapy administration will have broad therapeutic applications for lung cancer treatment.


   Acknowledgments
 
Grant support: National Cancer Institute grants CA083185 and CA077263 (S.B. Horwitz); National Foundation for Cancer Research (S.B. Horwitz); AACR-Amgen, Inc. Fellowship in Translational Cancer Research (H.M. McDaid); and Spanish Secretaria de Estado de Universidades e Investigacion, Ministerio de Educacion Cultura y Deporte and Fondo Social Europeo postdoctoral fellowship (L. Lopez-Barcons).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Drs. Judith Sebolt-Leopold and Wilbur Leopold and Curtis Howard (Pfizer); Sandra Goodman, RN; Drs. Joseph Locker and George Orr; and the Histotechnology and Comparative Pathology, and Analytical Imaging Facilities at Albert Einstein College of Medicine.


   Footnotes
 
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org).

Received 12/ 9/04. Revised 1/21/05. Accepted 1/26/05.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Cohen P. Protein kinases: the major drug targets of the twenty-first century? Nat Rev Drug Discov 2002;4:309–15.
  2. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004;23:2838–49.[CrossRef][Medline]
  3. Cox A, Der C. The dark side of Ras: regulation of apoptosis. Oncogene 2003;22:8999–9006.[CrossRef][Medline]
  4. Wan P, Garnett M, Roe S, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855–67.[CrossRef][Medline]
  5. Seger R, Ahn N, Posada J, et al. Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 1992;267:14373–81.[Abstract/Free Full Text]
  6. Ferrell JJ. Tripping the switch fantastic: how a protein kinase cascade can convert graded inputs into switch-like outputs. Trends Biochem Sci 1996;21:460–6.[CrossRef][Medline]
  7. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813–22.[CrossRef][Medline]
  8. Dhillon A, Kolch W. Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 2004;5:303–4.[CrossRef][Medline]
  9. Allen L, Sebolt-Leopold J, Meyer M. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 2003;5:105–16.
  10. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456–62.[Abstract/Free Full Text]
  11. Ohren JF, Chen H, Pavlovsky A, et al. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 2004;11:1192–7.[CrossRef][Medline]
  12. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153–83.[Abstract/Free Full Text]
  13. Liu X, Yan S, Zhou T, Terada Y, Erikson R. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene 2004;23:763–76.[CrossRef][Medline]
  14. Verlhac M, de Pennart H, Maro B, Cobb M, Clarke H. MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes. Dev Biol 1993;158:330–40.[CrossRef][Medline]
  15. Sette C, Barchi M, Bianchini A, et al. Activation of the mitogen-activated protein kinase ERK1 during meiotic progression of mouse pachytene spermatocytes. J Biol Chem 1999;274:33571–9.[Abstract/Free Full Text]
  16. Horne MM, Guadagno TM. A requirement for MAP kinase in the assembly and maintenance of the mitotic spindle. J Cell Biol 2003;161:1021–8.[Abstract/Free Full Text]
  17. Zecevic M, Catling AD, Eblen ST, et al. Active MAP kinase in mitosis: localization at kinetochores and association with the motor protein CENP-E. J Cell Biol 1998;142:1547–58.[Abstract/Free Full Text]
  18. Reszka A, Seger R, Diltz C, Krebs E, Fischer E. Association of mitogen-activated protein kinase with the microtubule cytoskeleton. Proc Natl Acad Sci 1995;92:8881–5.[Abstract/Free Full Text]
  19. Reszka A, Bulinski J, Krebs E, Fischer E. Mitogen-activated protein kinase/extracellular signal-regulated kinase 2 regulates cytoskeletal organization and chemotaxis via catalytic and microtubule-specific interactions. Mol Biol Cell 1997;8:1219–32.[Abstract]
  20. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (Taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol 2001;60:290–301.[Abstract/Free Full Text]
  21. MacKeigan JP, Collins TS, Ting JP-Y. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000;275:38953–6.[Abstract/Free Full Text]
  22. Yacoub A, Han S, Caron R, et al. Sequence dependent exposure of mammary carcinoma cells to Taxotere and the MEK1/2 inhibitor U0126 causes enhanced cell killing in vitro. Cancer Biol Ther 2003;2:670–6.[Medline]
  23. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932–8.[Abstract/Free Full Text]
  24. Golubkov V, Hawes D, Markland FS. Anti-angiogenic activity of contortrostatin, a disintegrin from Agkistrodon contortrix contortrix snake venom. Angiogenesis 2003;6:213–24.[CrossRef][Medline]
  25. Kubota T, Matsuzaki SW, Hoshiya Y, et al. Antitumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice. J Surg Oncol 1997;64:115–21.[CrossRef][Medline]
  26. Esteban E, Gonzalez de Sande L, Fernandez Y, et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Ann Oncol 2003;14:1640–7.[Abstract/Free Full Text]
  27. Giuliani N, Lunghi P, Morandi F, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia 2004;18:628–35.[CrossRef][Medline]
  28. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707–17.[Abstract/Free Full Text]
  29. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999;286:1741–4.[Abstract/Free Full Text]
  30. Rommel C, Clarke BA, Zimmermann S, et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 1999;286:1738–41.[Abstract/Free Full Text]
  31. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt cross-talk. J Biol Chem 2002;277:31099–106.[Abstract/Free Full Text]
  32. MacKeigan JP, Taxman DJ, Hunter D, et al. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition. Clin Cancer Res 2002;8:2091–9.[Abstract/Free Full Text]
  33. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004;40:802–20.
  34. Wabnitz PA, Mitchell D, Wabnitz DA. In vitro and in vivo metabolism of the anti-cancer agent CI-1040, a MEK inhibitor, in rat, monkey, and human. Pharm Res 2004;21:1670–9.[Medline]
  35. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777–84.[Abstract/Free Full Text]
  36. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785–94.[Abstract/Free Full Text]
  37. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res 2004;10:4233–7S.[CrossRef]
  38. Solit D, She Y, Moasser M, et al. Pulsatile administration of the EGF receptor inhibitor gefitinib (Iressa, ZD1839) is significantly more effective than continuous dosing for sensitizing tumors to Taxol. Proc AACR 2003;44:A83.
  39. Perez-Soler R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin Cancer Res 2004;10:4238–40S.[CrossRef]
  40. Zinner RG, Glisson BS, Fossella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004;44:99–110.[CrossRef][Medline]
  41. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 2004;25:2053–9.[Abstract/Free Full Text]
  42. Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857–68.[CrossRef][Medline]
  43. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231–41.[CrossRef][Medline]
  44. Mirza AM, Gysin S, Malek N, et al. Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT. Mol Cell Biol 2004;24:10868–81.[Abstract/Free Full Text]
  45. Sinha D, Bannergee S, Schwartz JH, Lieberthal W, Levine JS. Inhibition of ligand-independent ERK1/2 activity in kidney proximal tubular cells deprived of soluble survival factors up-regulates Akt and prevents apoptosis. J Biol Chem 2004;279:10962–72.[Abstract/Free Full Text]
  46. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004;6:117–27.[CrossRef][Medline]
  47. Sohn SJ, Sarvis BK, Cado D, Winoto A. ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. J Biol Chem 2002;277:43344–51.[Abstract/Free Full Text]
  48. Regan CP, Li W, Boucher DM, et al. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci U S A 2002;99:9248–53.[Abstract/Free Full Text]
  49. Mody N, Leitch J, Armstrong C, Dixon J, Cohen P. Effects of MAP kinase cascade inhibitors on the MKK5/ERK5 pathway. FEBS Lett 2001;502:21–4.[CrossRef][Medline]
  50. Brognard J, Dennis PA. Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 2002;9:893–904.[CrossRef][Medline]
  51. Borsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998;273:28766–72.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
R. W. Alfano, S. H. Leppla, S. Liu, T. H. Bugge, C. J. Meininger, T. C. Lairmore, A. F. Mulne, S. H. Davis, N. S. Duesbery, and A. E. Frankel
Matrix Metalloproteinase-Activated Anthrax Lethal Toxin Inhibits Endothelial Invasion and Neovasculature Formation during In vitro Morphogenesis
Mol. Cancer Res., April 1, 2009; 7(4): 452 - 461.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
A. SZANTO, Z. BOGNAR, A. SZIGETI, A. SZABO, L. FARKAS, and F. GALLYAS Jr.
Critical Role of Bad Phosphorylation by Akt in Cytostatic Resistance of Human Bladder Cancer Cells
Anticancer Res, January 1, 2009; 29(1): 159 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Wasylyk, H. Zheng, C. Castell, L. Debussche, M.-C. Multon, and B. Wasylyk
Inhibition of the Ras-Net (Elk-3) Pathway by a Novel Pyrazole that Affects Microtubules
Cancer Res., March 1, 2008; 68(5): 1275 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
H. Hamed, W. Hawkins, C. Mitchell, D. Gilfor, G. Zhang, X.-Y. Pei, Y. Dai, M. P. Hagan, J. D. Roberts, A. Yacoub, et al.
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo
Mol. Cancer Ther., March 1, 2008; 7(3): 616 - 629.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. B. Friday and A. A. Adjei
Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy
Clin. Cancer Res., January 15, 2008; 14(2): 342 - 346.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. K. Haass, K. Sproesser, T. K. Nguyen, R. Contractor, C. A. Medina, K. L. Nathanson, M. Herlyn, and K. S.M. Smalley
The Mitogen-Activated Protein/Extracellular Signal-Regulated Kinase Kinase Inhibitor AZD6244 (ARRY-142886) Induces Growth Arrest in Melanoma Cells and Tumor Regression When Combined with Docetaxel
Clin. Cancer Res., January 1, 2008; 14(1): 230 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M.-E. Legrier, C.-P. H. Yang, H.-G. Yan, L. Lopez-Barcons, S. M. Keller, R. Perez-Soler, S. B. Horwitz, and H. M. McDaid
Targeting Protein Translation in Human Non Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
Cancer Res., December 1, 2007; 67(23): 11300 - 11308.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
N. M. Mhaidat, R. F. Thorne, X. D. Zhang, and P. Hersey
Regulation of Docetaxel-Induced Apoptosis of Human Melanoma Cells by Different Isoforms of Protein Kinase C
Mol. Cancer Res., October 1, 2007; 5(10): 1073 - 1081.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
B. R. Davies, A. Logie, J. S. McKay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, and P. D. Smith
AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models
Mol. Cancer Ther., August 1, 2007; 6(8): 2209 - 2219.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Ji, Z. Wang, S. A. Perera, D. Li, M.-C. Liang, S. Zaghlul, K. McNamara, L. Chen, M. Albert, Y. Sun, et al.
Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models
Cancer Res., May 15, 2007; 67(10): 4933 - 4939.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. M. Mhaidat, X. D. Zhang, C. C. Jiang, and P. Hersey
Docetaxel-Induced Apoptosis of Human Melanoma Is Mediated by Activation of c-Jun NH2-Terminal Kinase and Inhibited by the Mitogen-Activated Protein Kinase Extracellular Signal-Regulated Kinase 1/2 Pathway
Clin. Cancer Res., February 15, 2007; 13(4): 1308 - 1314.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. M. Chin and R. Herbst
Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.
Mol. Cancer Ther., October 1, 2006; 5(10): 2580 - 2591.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. H. Davis
Profile of Susan Band Horwitz
PNAS, July 5, 2006; 103(27): 10163 - 10165.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McDaid, H. M.
Right arrow Articles by Band Horwitz, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McDaid, H. M.
Right arrow Articles by Band Horwitz, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online